Retatrutide, a innovative dual-acting glucose-regulated incretin analog, represents a significant leap in peptide treatments for the handling of type 2 sugar disorders and, increasingly, obesity. Unlike many existing medicinal interventions, retatrutide integrates the actions of a GLP-1 receptor activator and a GIP receptor activator, offering a mo